Cost-effectiveness of the HIT programme in patients with schizophrenia and persistent auditory hallucinations
Abstract:Stant AD, TenVergert EM, Groen H, Jenner JA, Nienhuis FJ, van de Willige G, Wiersma D. Cost-effectiveness of the HIT programme in patients with schizophrenia and persistent auditory hallucinations.
Acta Psychiatr Scand 2003: 107: 361–368. © Blackwell Munksgaard 2003. Objective:
To examine the cost-effectiveness of Hallucination focused Integrative Treatment (HIT) in patients with schizophrenia and a history of persistent auditory hallucinations. Method:
Costs, in and outside the health care sector, and outcomes were registered prospectively during a period of 18 months for patients who received the HIT programme and for patients in the care as usual (CAU) condition. The Positive and Negative Syndrome Scale (PANSS) was used as main outcome measure in the cost-effectiveness analysis. Bootstrap analyses provided additional information on the skewly distributed costs. Results:
Mean costs per patient in the HIT group ($18 237) were lower than the mean costs per patient in the CAU group ($21 436). Results of the PANSS were slightly in favour of the HIT group. Conclusion:
There appears to be no significant cost-effectiveness advantage of the HIT programme over CAU. Additional analyses indicated that future application of the HIT programme will, in most cases, lead to a reduction of (non) medical costs.
Document Type: Research Article
Publication date: May 1, 2003